Genmab A's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Genmab A (GMAB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Genmab A vs Its Competitors
- TTM: Trailing 12-month revenue of 3,720M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Scale: Genmab A ranks #88 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Genmab A accounted for 100.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
GMAB Sales vs. its Competitors, Q4 2025
Genmab A generated 100.00 % of the combined sales of its peer group.
Genmab A's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Genmab A | Yes | Yes | Yes | Yes |
| High-Confidence Competitors (10) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 62.50 % (5 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GMAB Stock Performance relative to its Competitors
GMAB Stock Performance relative to High-Confidence Competitors
GMAB Stock Performance relative to Similar-Size Competitors
GMAB Stock Performance relative to Similar Growth & Profitability Competitors
Genmab A's Comment on Competition and Industry Peers
Genmab A's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Ernexa Therapeutics Inc | Named by the company | 85% |
| Macrogenics Inc | Named by the company | 85% |
| Biontech Se | Named by the company | 85% |
| Inhibrx Biosciences Inc | Named by the company | 85% |
| Abcellera Biologics Inc | Named by the company | 85% |
| AbbVie | Named by the company | 85% |
| Nextcure Inc | Named by the company | 85% |
| Corbus Pharmaceuticals Holdings Inc | Named by the company | 85% |
| Iovance Biotherapeutics inc | Named by the company | 85% |
| Biohaven Ltd | Named by the company | 85% |
| Medarex, Inc. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Genmab A's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.